Ipilimumab

Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs. 3.1 months, HR: 0.42, 58% reduction in risk of disease progression Significantly improved ORR (37.1% vs 5.8%) and DCR (73.3% vs. 31.1%) by BICR vs. ICT, where ~77% were treated with ipilimumab + nivolumab OS not yet mature but early trend favoring the darovasertib combination; targeting to provide the next update as part of the pre-specified interim analysis Manageable safety profile consistent with prior results, with a low rate of TR-SAE (9.2%) and discontinuations due to TRAEs for darovasertib (2.5%) and crizotinib (10%) NDA submission in process under RTOR program; expect to complete filing in H2 2026 SOUTH SAN FRANCISCO, Calif., June 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Servier, an independent international pharmaceutical group governed by a foundation, today presented complete data from the primary analysis of their registrational Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib (darovasertib combination) in first line (1L) HLA*A2:01 negative metastatic uveal melanoma (mUM) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois. The data were provided in a late-breaking oral presentation by Dr. Marlana Orloff, M.D., Professor of Medical Oncology at Thomas Jefferson University Hospital and lead investigator on the trial. A copy of the presentation will be available on IDEAYA's corporate website. "The data from OptimUM-02 represent an exciting step forward in the treatment landscape for metastatic uveal melanoma, particularly for patients with HLA*A2:01 negative disease who have no approved treatment options," said Dr. Orloff. "The darovasertib combination drove consistent, robust and clinically meaningful improvements in response rate and progression free survival relative to checkpoint inhibitors that are commonly used today and supports its potential as a new therapeutic standard for patients with this devastating disease." OptimUM-02 is a global, registrational Phase 2/3 trial evaluating a total of 313 patients with 1L HLA*A2:01 negative mUM, randomized 2:1 to the darovasertib combination or an investigator's choice of therapy (ICT) arm reflective of real-world clinical practice that included ipilimumab plus nivolumab (anti-CTLA-4/PD-1) or pembrolizumab (anti-PD-1). The primary endpoint to support accelerated approval is median progression-free survival (PFS) as assessed by blinded independent central review (BICR). Secondary endpoints include safety and investigator assessed PFS, overall response rate (ORR), disease control rate (DCR) and duration of response. Data presented at ASCO were as of a cutoff date of January 23, 2026 and included additional detail on baseline characteristics as well as safety, secondary endpoints and median PFS across patient subgroups. Key Findings from OptimUM-02 Primary endpoint (Phase 2 portion): progression free survival by BICR The trial met the primary endpoint, with patients treated with the darovasertib combination demonstrating a statistically significant improvement in median PFS of 6.9 months versus 3.1 months in the ICT arm by BICR (HR: 0.42; 95% CI: 0.30, 0.59; p-value: <0.0001). Patients treated with the darovasertib combination also had a statistically significant improvement in median PFS of 6.7 months versus 2.7 months for ICT by investigator assessment (HR: 0.36; 95% CI: 0.26, 0.50, p-value: <0.0001). Notably, the darovasertib combination reduced the risk of disease progression by 58% and 64% as assessed by BICR and investigator assessment, respectively. Treatment with the darovasertib combination demonstrated a consistent and meaningful improvement in median PFS relative to the ICT arm across a broad range of patient subgroups, including age and gender, type of immune therapy used in ICT, LDH stratification, ECOG status and site of metastasis. Secondary endpoints: ORR, DCR, duration of response Patients treated with the darovasertib combination had an ORR of 37.1% (78/210) and 39.5% (83/210) as assessed by BICR and investigator, respectively, compared to 5.8% (6/103) and 1.9% (2/103) in the ICT arm (p-value: <0.0001). The darovasertib combination led to a disease control rate of 73.3% (154/210) and 74.3% (156/210) by BICR and investigator assessment, respectively, compared to 31.1% (32/103) and 27.2% (28/103) in the ICT control arm. The median duration of response was 6.8 months (95% CI: 5.5, 11.3) by BICR and 6.8 months (95% CI: 4.8, 9.7) by investigator assessment based on a median follow-up time of 7.4 months as of the cutoff date. Overall survival (Primary endpoint of the Phase 3 portion) As noted in the topline results, data on overall survival (OS) was still immature as of the cutoff date, however, there was an early trend in OS improvement in the darovasertib combination arm relative to the ICT arm. IDEAYA will provide the next OS update as part of the pre-specified interim analysis. Overall survival data, when available, will be used to support a potential full approval in the United States and globally. Safety The darovasertib combination was generally well-tolerated with a manageable safety profile consistent with previous results and known side-effects of each agent alone. Median relative dose intensities of darovasertib and crizotinib were 91.0% and 77.1%, respectively, compared to 100% for the ICT arm. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 40.6% (97/239) of patients in the darovasertib combination arm compared to 37.0% (37/100) of patients in the ICT control arm. Treatment-related serious adverse events (TR-SAE) were 9.2% (22/239) and 25.0% (25/100) in the darovasertib combination and ICT arms, respectively. Low discontinuation rate due to TRAEs for darovasertib (2.5%) and crizotinib (10.0%) relative to ICT (19.0%). The most common Grade 3/4 TRAEs included diarrhea (10.0%), syncope (7.1%) and hypotension (3.8.%) in the darovasertib combination arm compared to elevated liver enzymes (ALT, 7.0% / AST, 7.0%), diarrhea (6.0%), hepatitis (5.0%) and colitis (4.0%) in the ICT control arm. In April 2026, IDEAYA announced the U.S. Food and Drug Administration (FDA) has agreed to review their new drug application (NDA) for darovasertib in combination with crizotinib under the Oncology Center of Excellence Real-time Oncology Review (RTOR) program. This program allows applicants to pre-submit components of their NDA to allow the FDA to review clinical trial data before the complete filing is submitted and aims to provide a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. IDEAYA completed its first pre-submission in May and expects to complete the NDA filing in the second half of 2026. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. About Servier Servier is an independent international pharmaceutical group governed by a foundation. With its governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. The Group intends to offer targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. More information on the Group website: servier.com  Follow us on social media: LinkedIn, Facebook, X, Instagram  Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefit, safety, tolerability and clinical activity of darovasertib in combination with crizotinib; the potential significance and implications of data from the Phase 2/3 registrational OptimUM-02 trial; expectations regarding overall survival analyses and timing of interim data updates; IDEAYA's plans and expectations regarding regulatory submissions, including the timing and completion of the NDA submission under the FDA's Real-Time Oncology Review (RTOR) program; the potential for accelerated approval and/or full approval of darovasertib in combination with crizotinib in the United States and globally; and IDEAYA's strategy, business plans and objectives. Such forward-looking statements are based on IDEAYA's current expectations, estimates, assumptions, and beliefs regarding future events and are subject to substantial risks and uncertainties that could cause actual results, outcomes or events to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others: risks related to the discovery, development and regulatory approval of drug candidates; risks related to the timing, progress and results of clinical trials, including uncertainties regarding enrollment, safety, efficacy and durability of response; risks that clinical trial results may not be replicated in future studies or support regulatory approval; risks related to regulatory interactions, submissions and decisions, including the timing and outcome of NDA review processes; risks related to manufacturing and supply; risks related to competition and changes in the standard of care; the timing and success of commercialization efforts; the outcome of collaborations and licensing arrangements; IDEAYA's dependence on third parties; risks related to intellectual property protection; and risks related to IDEAYA's ability to obtain, maintain and enforce intellectual property rights for its product candidates. Additional risks and uncertainties that could affect IDEAYA's business and results are described under the caption "Risk Factors" in IDEAYA's filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Forward-looking statements contained in this press release are made only as of the date hereof, and IDEAYA undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investor and Media Contacts IDEAYA Biosciences Joshua Bleharski, Ph.D. Chief Financial Officer [email protected] Servier Laura Visserias [email protected] SOURCE IDEAYA Biosciences, Inc. 21% more press release views with Request a Demo

如果把过去十年的肿瘤免疫治疗（Immuno-Oncology，IO）写成一部行业史，PD-1/PD-L1抑制剂无疑是绝对主角。从默沙东K药、百时美施贵宝O药，到信迪利单抗、替雷利珠单抗、卡瑞利珠单抗等一批中国产品，这一类药物以“松开免疫刹车”为核心机制，重塑了非小细胞肺癌（NSCLC）、黑色素瘤、肾癌、胃癌、食管癌、肝癌等多个瘤种的一线治疗格局。 但与此同时，PD-1/PD-L1单抗的“天花板”也在临床实践中一点点显露出来： ● 客观缓解率（ORR）有限：多数瘤种里PD-1单药ORR只有20%—30%左右，意味着大部分患者并不能从单药免疫治疗中直接获益； ● 存在原发耐药与继发耐药：一部分患者从一开始就对PD-1完全无应答（原发耐药），还有一部分患者起初有效，但在使用一段时间后肿瘤再度进展（继发耐药）； ● PD-L1低表达/阴性人群获益更弱：肿瘤细胞表面PD-L1表达水平越低，PD-1单抗的疗效通常越差，这部分患者一直缺少更好的免疫治疗方案。 正因如此，全球IO领域近几年的核心命题已经变化——在PD-1这个骨架上“做加法”，提高响应率、克服耐药、覆盖更广人群。中国药企免疫疗法在PD-1之后亮出了三条清晰的技术路线，ASCO 2026正是这个命题的重要观察窗口。 第一，三条路线针对的是不同人群、不同临床场景。它们之间不一定是直接竞争关系——PD-1×VEGF更多瞄准一线大瘤种、与PD-1单抗正面对决；PD-1×IL-2选择PD-1薄弱地带做差异化；PD-1×VEGF×CTLA-4则在更广义的瘤种和线数里探索协同。这意味着未来下一代IO的格局很可能不是“赢家通吃”，而是按人群和瘤种分层共存。 第二，中国在三条路线已经站在全球第一梯队。依沃西进入ASCO 2026 Plenary、IBI363获得武田引进、CS2009是全球首创三抗。这意味着，中国IO研发已经从“复制PD-1”阶段走到了“定义下一代骨架”阶段，这是产业层面最重要的变化。 第三，“做加法”的核心矛盾永远是疗效与毒性的平衡。机制叠加越多，潜在毒性叠加的风险越高。CTLA-4尤为典型——历史上其与PD-1的联用因毒性问题屡屡受挫。CS2009在I期数据中安全性表现良好是亮点，但能否在Ⅲ期、在更长随访中保持，是这条路线的核心看点之一。 01 路线一：最火赛道，PD-1×VEGF双抗 由于具备“免疫激活+抗血管生成”的协同抗肿瘤增效机制，PD-1/VEGF双抗被视为极有潜力迭代PD-1单抗的下一代疗法，同时是MNC扫货的重点管线。 PD-1/PD-L1，可以理解为免疫系统的“刹车”。正常情况下，T细胞通过PD-1这个分子接收“停止攻击”的信号，避免误伤正常组织；但很多肿瘤细胞会“狡猾地”在自己表面表达PD-L1，主动按下T细胞的刹车，从而逃避免疫攻击。PD-1/PD-L1抑制剂的作用，就是把这个刹车强行松开。 VEGF（血管内皮生长因子）是促进新血管生成的关键信号分子，肿瘤往往大量分泌VEGF来“自建供血管线”。抗VEGF药物（如贝伐珠单抗）正是切断这一供血。近年来研究还发现，VEGF不仅“喂饱”肿瘤，还参与塑造一种压制免疫细胞的肿瘤微环境——这是PD-1×VEGF联合的重要机制依据。 PD-1×VEGF双特异性抗体的核心思路，是把两种已经各自验证有效的机制装入一个分子内： ● 一端结合PD-1：解除T细胞的免疫刹车； ● 另一端结合VEGF：抑制肿瘤血管生成，同时改造免疫抑制性微环境。 这两种机制看似分立，其实彼此呼应——VEGF高表达的肿瘤往往伴随更“冷”的免疫环境（T细胞难以浸润、调节性T细胞与抑制性髓系细胞富集），单纯松开PD-1有时无济于事；而联用抗VEGF能让肿瘤微环境向“热肿瘤”转变，让PD-1抑制剂的效果释放出来。 康方生物全球首创PD-1/VEGF双抗依沃西单抗（Ivonescimab）是这条路线最受关注的产品之一，也是本届ASCO 2026唯一进入Plenary Session（全体大会）的中国研究，于6月1日大会上正式报告。 5月31日《柳叶刀》发布的数据显示，Ⅲ期HARMONi-6/AK112-306研究中，【依沃西联合化疗】对比【替雷利珠单抗联合化疗】，用于一线治疗晚期鳞状非小细胞肺癌（sq-NSCLC）的OS（总生存期）呈现显著阳性结果。HARMONi-6研究共入组532例受试者，中央型鳞癌占比约为63%，PD-L1 TPS＜1%占比为39.0%，肿瘤多部位转移/肝转移/脑转移患者占比约33.8%。 经IDMC评估的预先设定的期中分析结果显示，研究达到主要终点、所有关键次要终点及全部次要终点，包括取得具有临床获益和统计学显著获益PFS和OS阳性结果，安全性特征可控，与既往研究结果一致。研究结果显示，相比于替雷利珠单抗联合化疗，依沃西联合化疗可显著延长患者OS。相对于PD-1联合化疗，依沃西联合化疗的肺癌死亡风险进一步下降了34%。 此前，作为全球首个且唯一获批上市的首创PD-1/VEGF双抗，康方生物依沃西单抗在与帕博利珠单抗的头对头试验中胜出，成为全球首个且唯一在单药头对头Ⅲ期临床研究中证明疗效显著优于K药的药物，为双抗联合ADC奠定了关键的安全性基础，再为PD-1/VEGF赛道添了一把火。 商业端来看，2025年，康方生物达成30.33亿元新药销售收入，主要来源于依沃西单抗和开坦尼（卡度尼利单抗）。在EGFR-TKI耐药的非小细胞肺癌适应症上，依沃西单抗是目前全球唯一在PFS（无进展生存期）和OS（总生存期）上均取得显著阳性结果的免疫疗法。2025年底，其一线治疗PD-L1阳性非小细胞肺癌的适应症成功新增纳入国家医保，预计2026年将进一步放量。今年1月JPM 2026期间，Summit表示，已经向美国FDA递交依沃西单抗的上市申请。 BD端，PD-1/VEGF双抗几乎是国内创新药跨境BD史上最热门、出售金额最高的管线类型，形成了典型的in China for Global的格局。据《财经》报道，截至2025年7月，全球13款在研PD-1/VEGF双抗，8款出自中国企业，进入临床阶段的7款，6款来自中国；PD-L1/VEGF双抗全球15款在研，10款来自中国，6款临床阶段新药全部由中国企业研发。 全球前十大MNC中，已有4家通过BD交易布局该赛道，形成了激烈“第二梯队”格局： ● 礼新医药/默沙东（LM-299）：2024年11月以5.88亿美元首付款、最高27亿美元里程碑付款授权给默沙东。 ● 三生制药/辉瑞（SSGJ-707）：2025年5月以12.5亿美元首付款、总交易额60.5亿美元授权给辉瑞。 ● 普米斯生物/BioNTech/BMS（PM8002）：2025年6月，BMS就普米斯PD-L1/VEGF双抗与BioNTech达成合作，首付款达15亿美元，潜在总交易额111亿美元，转手差价高达90亿美元。 ● 荣昌生物/艾伯维（RC148）：2026年1月，以6.5亿美元首付款、最高达49.5亿美元的里程碑付款，高达56亿美元的交易总额，授予艾伯维在大中华区以外地区的开发、生产和商业化的独家权利。 02 路线二：PD-1×IL-2融合蛋白 信达生物的IBI363（TAK-928）走的是另一条路——“检查点阻断 + 细胞因子激活”双机制。 IL-2（白细胞介素-2）是一种能强力激活和扩增T细胞的细胞因子，是免疫系统的“油门”。早期高剂量IL-2确实在少数瘤种里展现过完全缓解效果，但毒性极大，临床应用受限。下一代设计思路是α-bias——只激活有利于扩增有效T细胞的IL-2受体亚基，绕开会带来毒性的支路。 IBI363是全球首创的PD-1/IL-2α-biased双特异性抗体融合蛋白/偏向型双抗，聚焦PD-1耐药、冷肿瘤、PD-L1低表达肿瘤的治疗瓶颈。它的两端各司其职： ● 一端结合PD-1，松开T细胞的免疫刹车：PD-1结合臂可同时实现对PD-1的阻断和IL-2的选择性递送。 ● 另一端“α-bias”激活IL-2通路，踩下油门、扩增有效的肿瘤特异性T细胞：IBI363的IL-2臂经过了设计改造，保留了其对IL-2 Rα的亲和力，但削弱了对IL-2Rβ和IL-2Rγ的结合能力，以此降低毒性。 ASCO 2026上，IBI363拿出了两组方向截然不同但同样关键的数据： (1) 瞄准无治疗选择的后线NSCLC耐药患者，显示长期生存获益 研究显示，在已经对PD-1/PD-L1治疗失败的晚期鳞状与腺性NSCLC人群中，IBI363均显示出强劲的OS获益。对于无驱动基因突变、既往接受过免疫治疗后进展的晚期NSCLC患者，后续治疗选择有限，临床上通常依赖多西他赛等化疗方案。如果一款新机制免疫药能在这一人群中显示较长生存获益，意味着确实“打到了PD-1打不到的位置”。 此次ASCO摘要更新显示，截至2025年11月20日，共136例NSCLC受试者接受了IBI363单药治疗。该剂量组患者取得了令人瞩目的生存结果：中位无进展生存期（PFS）达到10.1个月，中位总生存期（OS）达到18.2个月，24个月总生存率高达47.8%。换言之，接近一半患者在接受治疗两年后仍保持生存状态。随着随访时间延长，生存曲线后段逐渐趋于平缓，呈现出典型的免疫治疗长期获益特征。 此外，在EGFR野生型肺腺癌患者（N=58）中，3mg/kg剂量组中位OS为15.2个月，24个月OS率为42.7%；其中有吸烟史受试者的中位OS达到23.4个月。 (2) 一线NSCLC（PD-L1阴性/低表达）的初步PoC PD-L1阴性或低表达的NSCLC同样是PD-1单抗的薄弱地带——肿瘤细胞表面几乎没有PD-L1表达，理论上“刹车信号”本身就不强，松开它意义有限，因此该人群对K药、O药等单药响应较差。 一线治疗晚期非小细胞肺癌的初步PoC临床研究数据中，IBI363 联合化疗用于PD-L1 阴性或低表达晚期非小细胞肺癌（NSCLC）一线治疗，展现出优异的疗效和良好的安全性信号；同时，在鳞癌与非鳞癌亚组、PD-L1 阴性及低表达人群中均展现出亮眼疗效。 入组的80名患者中，3→1.5 mg/kg剂量组（n=22）客观缓解率（ORR）达 86.4%，确认客观缓解率（cORR）81.8%，疾病控制率（DCR）100%。3→1.5mg/kg指的是诱导期高剂量、维持期减量的递减给药策略——初期快速起效，同时控制长期治疗的累积毒性是针对IL-2类药物毒性特点的工程化设计。 把这两组数据合起来看，IBI363的产品定位非常清晰——它瞄准的不是与PD-1单抗“正面竞争”的人群，而是PD-1单抗尚未打透的两块阵地： ● IO耐药：PD-1失败之后的患者； ● PD-L1低表达/阴性：从一开始PD-1就无能为力的患者。 这种差异化对应的产业语言是“互补”而不是“替代”。进一步探索分层用药格局——PD-1单抗用于PD-L1高表达初治；PD-1×IL-2用于PD-L1低表达或PD-1失败。 2025年10月，信达生物与武田制药达成总金额达114亿美元的交易，IBI363和IBI343的相关权益包含在内。其中，武田制药获得IBI363的全球共同开发和美国商业化权益，和IBI343大中华区外的独家授权。 03 路线三：PD-1×VEGF×CTLA-4三抗 作为PD-1之外另一个重要的免疫检查点，CTLA-4抑制剂（如伊匹木单抗）单用或与PD-1联用能进一步提升缓解率，但代价是显著增加免疫相关不良反应（皮疹、肠炎、肝炎、内分泌异常等），如何在加强疗效的同时控制毒性，是CTLA-4类药物长期未解的难题。 基石药业三抗CS2009把PD-1、VEGF、CTLA-4三个机制集于一身：PD-1与CTLA-4分别作用在免疫激活的不同环节，联用的疗效往往优于任一单药；再叠加VEGF则进一步打开肿瘤微环境的“门”，让免疫细胞能进得来、留得住、打得出，形成更强的协同，有望带来长期疗效的提升。 ● PD-1：解除T细胞表面的“近端刹车”； ● CTLA-4：作用于淋巴结内的T细胞初始激活阶段，解除T细胞活化早期阶段的“远端刹车”，并削弱抑制性Treg的功能； ● VEGF：抑制血管生成、改造肿瘤微环境。 ASCO2026的壁报展示CS2009在一线及后线NSCLC和CRC患者中的I/Ⅱ期临床试验数据，以及晚期实体瘤患者更长随访后的成熟I期临床数据： (1) PD-L1高表达的一线NSCLC，CS2009单药治疗的客观缓解率（ORR）达81.3%，疾病控制率（DCR）达100.0%，且鳞癌（ORR：87.5%）与非鳞癌（ORR：75.0%）亚组获益一致。在PD-L1阴性/低表达（TPS ≤5%）一线鳞状NSCLC队列中，CS2009联合化疗的ORR为75.0%，DCR为100.0%；其中PD-L1阴性患者的ORR达到100.0%。 (2) 在重度经治的后线NSCLC中，所有剂量组的6个月缓解持续时间（DOR）率达85.7%。联合治疗队列（二/三线）的ORR为66.7%，DCR为100.0%；在单药治疗（30 mg/kg）队列中，既往免疫治疗（IO）联合含铂化疗进展后的患者ORR达到30.8%，DCR达到84.6%。 (3) 在对免疫治疗应答有限的“冷肿瘤”中，CS2009单药治疗在重度经治的错配修复功能完整/微卫星稳定型转移性结直肠癌（pMMR/MSS mCRC）队列中取得了25.0%的ORR和87.5%的DCR，展现出在免疫治疗获益受限领域的积极信号。 (4) 安全性：在重度经治的实体瘤患者中，≥3级治疗相关不良事件（TRAE）的发生率为24.6%，免疫相关不良事件（irAE）为12.7%，抗VEGF相关TRAE为5.1%。在一线NSCLC的单药和化疗联合队列中得到了持续一致的验证。 其中，安全性数据尤为关键。CTLA-4抑制剂以毒性大著称，伊匹木单抗+纳武利尤单抗（CTLA-4+PD-1）联用的≥3级免疫相关不良事件发生率历来较高，是这一组合在临床推广中的主要障碍。CS2009做到了在三机制叠加的同时控制住整体毒性轮廓。如果在更大样本和更长随访中得到延续，将是该分子最重要的差异化优势。 *封面图片来源：123rf 如果您认同文章中的观点、信息，或想进一步讨论，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。 近 期 推 荐 声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。文中如果涉及企业信息和数据，均由受访者向分析师提供并确认。 动脉网，未来医疗服务平台